Psoriasis – Pipeline Review, H1 2012
Reference Code: GMDHC1736IDB
Publication Date: February 2012
Psoriasis – Pipeline Review, H1 2012 GMDHC1736IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Psoriasis – Pipeline Review, H1 2012
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables ............................................................................................................................................................................... 11
List of Figures .............................................................................................................................................................................. 14
Introduction....................................................................................................................................................................................... 15
Global Markets Direct Report Coverage ...................................................................................................................................... 15
Psoriasis Overview ........................................................................................................................................................................... 16
Therapeutics Development............................................................................................................................................................... 17
An Overview of Pipeline Products for Psoriasis ........................................................................................................................... 17
Psoriasis Therapeutics under Development by Companies ............................................................................................................. 19
Psoriasis Therapeutics under Investigation by Universities/Institutes .............................................................................................. 28
Late Stage Products ......................................................................................................................................................................... 30
Comparative Analysis .................................................................................................................................................................. 30
Mid Clinical Stage Products.............................................................................................................................................................. 31
Comparative Analysis .................................................................................................................................................................. 31
Early Clinical Stage Products ........................................................................................................................................................... 32
Comparative Analysis .................................................................................................................................................................. 32
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 33
Comparative Analysis .................................................................................................................................................................. 33
Psoriasis Therapeutics – Products under Development by Companies ........................................................................................... 34
Psoriasis Therapeutics – Products under Investigation by Universities/Institutes ............................................................................ 43
Companies Involved in Psoriasis Therapeutics Development .......................................................................................................... 44
Bristol-Myers Squibb Company ................................................................................................................................................... 44
Genzyme Corporation ................................................................................................................................................................. 45
Johnson & Johnson ..................................................................................................................................................................... 46
Boehringer Ingelheim GmbH ....................................................................................................................................................... 47
Kyowa Hakko Kirin Co., Ltd. ........................................................................................................................................................ 48
Amgen Inc. .................................................................................................................................................................................. 49
Eli Lilly and Company .................................................................................................................................................................. 50
GlaxoSmithKline plc .................................................................................................................................................................... 51
Biotest AG ................................................................................................................................................................................... 52
Merck & Co., Inc. ......................................................................................................................................................................... 53
BioLineRx, Ltd. ............................................................................................................................................................................ 54
ApoPharma.................................................................................................................................................................................. 55
Celltrion, Inc................................................................................................................................................................................. 56
Novartis AG ................................................................................................................................................................................. 57
Isotechnika Pharma Inc. .............................................................................................................................................................. 58
Actelion Ltd .................................................................................................................................................................................. 59
Astellas Pharma Inc..................................................................................................................................................................... 60
Biocon Limited ............................................................................................................................................................................. 61
Cephalon, Inc. ............................................................................................................................................................................. 62
Dr. Reddy's Laboratories Limited................................................................................................................................................. 63
Eisai Co., Ltd. .............................................................................................................................................................................. 64
Psoriasis – Pipeline Review, H1 2012 GMDHC1736IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Psoriasis – Pipeline Review, H1 2012
Galderma S.A. ............................................................................................................................................................................. 65
LEO Pharma A/S ......................................................................................................................................................................... 66
Pfizer Inc...................................................................................................................................................................................... 67
Celgene Corporation ................................................................................................................................................................... 68
Incyte Corporation ....................................................................................................................................................................... 69
4SC AG ....................................................................................................................................................................................... 70
3SBio Inc. .................................................................................................................................................................................... 71
Addex Pharmaceuticals ............................................................................................................................................................... 72
InNexus Biotechnology Inc. ......................................................................................................................................................... 73
Can-Fite BioPharma Ltd. ............................................................................................................................................................. 74
Idera Pharmaceuticals, Inc. ......................................................................................................................................................... 75
Almirall, S.A. ................................................................................................................................................................................ 76
Astralis, Ltd. ................................................................................................................................................................................. 77
Lupin Limited ............................................................................................................................................................................... 78
Basilea Pharmaceutica Ltd. ......................................................................................................................................................... 79
NexMed, Inc. ............................................................................................................................................................................... 80
NicOx SA ..................................................................................................................................................................................... 81
CytoGenix, Inc. ............................................................................................................................................................................ 82
CombinatoRx, Incorporated ......................................................................................................................................................... 83
Protalix BioTherapeutics, Inc. ...................................................................................................................................................... 84
Tolerx, Inc. ................................................................................................................................................................................... 85
Genizon BioSciences, Inc............................................................................................................................................................ 86
Cytos Biotechnology AG .............................................................................................................................................................. 87
Biotie Therapies Corp. ................................................................................................................................................................. 88
Provectus Pharmaceuticals, Inc. ................................................................................................................................................. 89
Synta Pharmaceuticals Corp. ...................................................................................................................................................... 90
Sareum Holdings plc ................................................................................................................................................................... 91
Hybrigenics S.A. .......................................................................................................................................................................... 92
R-Tech Ueno, Ltd. ....................................................................................................................................................................... 93
Piramal Life Sciences Limited...................................................................................................................................................... 94
Paloma Pharmaceuticals, Inc. ..................................................................................................................................................... 95
D-Pharm Ltd. ............................................................................................................................................................................... 96
Affimed Therapeutics AG ............................................................................................................................................................ 97
Viron Therapeutics, Inc................................................................................................................................................................ 98
Jenrin Discovery, Inc. .................................................................................................................................................................. 99
Probiodrug AG ........................................................................................................................................................................... 100
Physica Pharma ........................................................................................................................................................................ 101
Phenex Pharmaceuticals AG ..................................................................................................................................................... 102
MIKA Pharma GmbH ................................................................................................................................................................. 103
Cosmix Molecular Biologicals GmbH......................................................................................................................................... 104
CREABILIS Therapeutics S.r.l. .................................................................................................................................................. 105
Anacor Pharmaceuticals, Inc. .................................................................................................................................................... 106
JADO Technologies GmbH. ...................................................................................................................................................... 107
AnaptysBio, Inc.......................................................................................................................................................................... 108
Psoriasis – Pipeline Review, H1 2012 GMDHC1736IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3)
Psoriasis – Pipeline Review, H1 2012
Circassia Holdings Ltd. .............................................................................................................................................................. 109
Therapeutics Incorporated ......................................................................................................................................................... 110
Allozyne, Inc. ............................................................................................................................................................................. 111
Oxagen Limited ......................................................................................................................................................................... 112
S*BIO Pte Ltd ............................................................................................................................................................................ 113
Vascular Biogenics Ltd. ............................................................................................................................................................. 114
Xention Limited .......................................................................................................................................................................... 115
Virobay Inc................................................................................................................................................................................. 116
Inimex Pharmaceuticals, Inc. ..................................................................................................................................................... 117
Welichem Biotech Inc. ............................................................................................................................................................... 118
ELORAC, Inc. ............................................................................................................................................................................ 119
ChemoCentryx, Inc. ...............................................................................................................................................................